rethinkPeptides Search
Menu
Study breakdown

Designed Antimicrobial Peptide Killed 75% of Drug-Resistant Acinetobacter Persister Cells

evidence
The takeaway

A computationally designed 20-amino acid antimicrobial peptide reduced Acinetobacter baumannii persister cells by 75% and inhibited biofilm formation with only moderate toxicity to human cells.

75% persister cell reduction

A designed antimicrobial peptide eliminated three-quarters of Acinetobacter baumannii persister cells within 24 hours — cells that conventional antibiotics cannot kill

What the researchers found

A bioinformatically designed 20-amino acid antimicrobial peptide demonstrated potent activity against Acinetobacter baumannii with an MIC of 64 µg/mL. The peptide reduced persister cell populations by 75% within 24 hours — a critical finding since persister cells are responsible for chronic and recurring infections. It also inhibited biofilm formation and altered expression of the pmrB and lasI genes involved in antibiotic resistance and quorum sensing. Cytotoxicity to mammalian cells was moderate (8–17% reduction in cell viability).

Why it matters

Acinetobacter baumannii is classified by the WHO as a critical-priority pathogen due to extensive antibiotic resistance. Persister cells and biofilms make it even harder to treat. This peptide's ability to target persister cells specifically — which conventional antibiotics cannot do — represents a potentially breakthrough approach to combating one of medicine's most challenging infections.

The numbers in context

20-amino acid peptide · MIC 64 µg/mL · 75% persister cell reduction in 24 h · 8–17% cytotoxicity to mammalian cells · biofilm reduction observed · pmrB and lasI gene expression altered

How the study worked

Computational peptide design using bioinformatics tools followed by chemical synthesis of a 20-amino acid peptide. In vitro testing included minimum inhibitory concentration (MIC) assays, persister cell killing assays, biofilm inhibition assays, cytotoxicity testing on mammalian cells, and quantitative PCR for gene expression changes in pmrB (antibiotic resistance) and lasI (quorum sensing).

Who was studied

Acinetobacter baumannii bacterial cultures including persister cell populations (in vitro laboratory study)

What this study cannot tell us

This is an in vitro study only — the peptide has not been tested in animals or humans. The moderate cytotoxicity (8–17%) to mammalian cells is a concern that would need to be addressed for therapeutic development. The specific mechanism of action against persister cells was not fully elucidated. Only one bacterial species was tested.

How to read the evidence

Early-stage in vitro laboratory study demonstrating proof of concept for a computationally designed antimicrobial peptide. While the results are promising, no in vivo data or clinical testing has been performed. The cytotoxicity data suggests further optimization is needed.

When this study was published

Published in 2025, this study addresses the urgent and growing problem of multidrug-resistant hospital infections using cutting-edge computational peptide design approaches.

The bigger picture

Antimicrobial peptides are increasingly viewed as alternatives to failing conventional antibiotics. The ability to target persister cells — dormant bacteria that survive standard treatment — is particularly valuable. This computationally designed approach allows rapid development of peptides tailored to specific pathogens, potentially accelerating the pipeline of new antimicrobials against critical-priority drug-resistant bacteria.

Questions still open

  • Can the cytotoxicity be reduced through peptide sequence optimization while maintaining antimicrobial activity?
  • Would this peptide show similar efficacy against persister cells in an animal infection model?
  • Could this computational design approach be applied to create antimicrobial peptides against other WHO critical-priority pathogens?

Common questions

What are persister cells and why are they so dangerous?
Persister cells are bacteria that enter a dormant state during antibiotic treatment. Because antibiotics typically work by disrupting active cellular processes, these sleeping bacteria survive the treatment. Once antibiotics are stopped, they wake up and can restart the infection, leading to chronic or recurring infections that are extremely difficult to cure.
Why use antimicrobial peptides instead of regular antibiotics?
Antimicrobial peptides kill bacteria through physical disruption of their cell membranes, which is harder for bacteria to evolve resistance against compared to the specific molecular targets of conventional antibiotics. They can also kill dormant persister cells that antibiotics miss, making them potentially valuable for treating the most drug-resistant infections.

Read the original research

In vitro assessment of an antimicrobial peptide against Acinetobacter baumannii persister cells.

Scientific reports, 16(1), 3226

Citation

Hosseini, Mandana; Hosseini, Farzaneh; Amirmozafari, Nour; Sepahy, Abbas Akhavan. (2025). In vitro assessment of an antimicrobial peptide against Acinetobacter baumannii persister cells.. Scientific reports, 16(1), 3226. https://doi.org/10.1038/s41598-025-33137-w